Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06626711

Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells

The goal of this clinical trial is to learn if sevoflurane-based inhalational anesthesia (s-IA) and propofol-based total intravenous anesthesia (p-TVA) have different effects on HSP70 expression in different types of tumour cells. The main questions it aims to answer are:

* if p-TVA/s-IA increase or suppress HSP70 expression in tumor cells in comparison with a pre-anesthesia level; * does this change in HSP70 expression cause any difference in vital characteristics of tumor cells, such as proliferation, apoptosis, colony formation and migration.

Researchers will compare p-TVA with s-IA by ability of these types of anesthesia to change the HSP70 expression level and modulate HSP70-mediated effects in tumor cells.

Participants will:

* be randomly allocated to p-TVA or s-IA groups; * donate 12 ml of blood before anesthesia induction and 12 ml after 2 hours of anesthesia.

The blood serum will be used to prepare cell medium. After exposure to this medium, cells from different tumor types will be investigated using cytological and molecular biological methods.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Anesthesia Cancer Cancer Recurrence Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Saint Petersburg State University Hospital

Saint Petersburg, 1999034, Russia

About this study

This study will be conducted in adult cancer patients who undergo planned radical or palliative tumor resection and signed informed consent. Patients with diabetes mellitus, HIV, hepatitis B and C, as well as patients who undergo emergency surgery will not be included to the study. Patients will be randomly allocated to propofol-based TVA (p-TVA) and sevoflurane-based IA (s-IA) groups. After the collection of blood before the anesthesia induction and in 2 hours of anesthesia, probes will be centrifuged to prepare serum. Cell medium will contain 50% of blood serum. Different tumor cell lines (human lung adenocarcinoma A549, large cell lung carcinoma NCI-H460, human colorectal adenocarcinoma DLD1) will be exposed to the cell medium for 4 hours what corresponds to an approximate duration of anesthesia for oncology surgery. HSP70 expression level will be determined using SDS-PAGE (polyacrilamide gel electrophoresis) and Western-blot analysis (intracellular HSP70 content), ELISA of cell medium (extracellular HSP70 expression) and confocal microscopy.

The A549 cell line with stable knockdown of HSP70 developed by shRNA will be used to distinguish HSP70-based effects of cell medium from p-TVA and s-IA groups on vital characteristics of tumor cells, including proliferation (MTT assay), apoptosis (LDH cytotoxicity assay), colony formation and migration (the Wound healing assay).

Researchers will compare HSP70 expression levels and vital characteristics of tumor cells exposed to patient serum before and after each type of anesthesia, as well as p-TVA group with s-IA group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed malignant neoplasm
  • Planned surgery for radical or palliative tumor resection
  • Age over 18 years
  • Signed informed consent

Exclusion criteria

  • Diabetes mellitus type 2
  • HIV, hepatitis B or C
  • Emergency surgery
  • Known or suspected allergy to studied drugs
  • Other conditions when one of the types of anesthesia is more preferable (hemodynamic disorders, bronchial asthma etc)

Treatment and study plan

Propofol

Drug

Propofol as a part of total venous anesthesia

Sevoflurane

Drug

Sevoflurane as a part of intravenous anesthesia

Primary outcomes

  1. HSP70 expression in tumor cells in vitro

    Time frame: 24 hours after exposition with patients serum.

    Increased intracellular and extracellular HSP70 content in different types of tumor cells measured by SDS-PAGE/Western blotting and ELISA, respectively.

Secondary outcomes

  1. LDG cytotoxicity

    Time frame: 24 hours after exposition with patients serum.

    Reduction of apoptosis mediated by HSP70 pathway in different types of tumor cells measured by LDG cytotoxicity assay using HSP70-knockdown cell line.

  2. MTT test

    Time frame: 24 hours after exposition with patients serum.

    Increase in proliferation mediated by HSP70 pathway in different types of tumor cells measured by MTT assay using HSP70-knockdown cell line.

  3. Wound healing test

    Time frame: 72 hours after exposition with patients serum.

    Increase in cell migration mediated by HSP70 pathway in different types of tumor cells measured by the Wound healing assay.

  4. Cell colonies formation

    Time frame: 7 days after exposition with patients serum.

    Increase in ability to form colonies mediated by HSP70 pathway in different types of tumor cells evaluated by direct microscopy using HSP70-knockdown cell line.

Sponsors and collaborators

Lead sponsor

Saint Petersburg State University, Russia

Other

Collaborators

  • Institute of Cytology of the Russian Academy of Sciences
  • The Russian Science Foundation

Registry information

Official study title

Effect of Propofol and Sevoflurane Anesthesia on HSP70 Expression in Tumor Cells A Prospective, Single-center, Pilot, Randomized Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 4, 2024
Registry last updated
May 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.